You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Pharmaceutical Advisory Committee

Our Pharmaceutical Advisory Committee shares our passion for pharmacology and the pursuit of making breakthrough medicines; they are thought-leaders in the world of drug discovery and pharmacology, and their deep scientific and medical expertise helps shape our discovery and early development efforts.

PERRY HALUSHKA, PH.D., M.D.
Medical University of South Carolina

Perry V. Halushka, Ph.D., M.D. is dean of the College of Graduate Studies and a professor of pharmacology and medicine at the Medical University of South Carolina. A world-renowned clinical pharmacologist, Dr. Halushka is recognized for his research contributions regarding the role of prostaglandins and thromboxanes in platelet functions and cardiovascular disease. He is a practicing physician and a member of numerous professional associations and editorial boards. Dr. Halushka is the recipient of PhRMA’s Clinical Pharmacology Award in Excellence, the Burroughs Wellcome Scholar in Clinical Pharmacology Award, and the William N. Creasy Award and Visiting Professor in Clinical Pharmacology. He is the author of more than 200 publications in peer-reviewed journals and more than 50 invited reviews and book chapters.

Michael Mendelsohn, M.D.
Cardurion Pharmaceuticals

Dr. Mendelsohn is a physician-scientist, research leader and executive with broad experience in healthcare. He brings extensive experience as an industry and academic leader in research and development with a focus on molecular and cellular cardiovascular biology. From 2010 through 2013, Dr. Mendelsohn was the senior vice president and head of cardiovascular research at Merck Research Laboratories, with overall responsibility for the scientific direction of cardiovascular research from drug discovery through late development. Dr. Mendelsohn joined SV Life Sciences as a venture partner in 2014, and in 2016 became executive chairman of Cardurion Pharmaceuticals, a cardiovascular company. Prior to Merck, Dr. Mendelsohn spent from 1993 to 2010 at Tufts Medical Center and Tufts University School of Medicine, where he served as the first chief scientific officer and was founder and executive director of the Molecular Cardiology Research Institute. From 1988 to 1993, he served on the cardiovascular faculty of Brigham and Women’s Hospital and Harvard Medical School. Dr. Mendelsohn completed an internal medicine internship and residency followed by a fellowship in cardiovascular medicine at Brigham and Women’s Hospital and Harvard Medical School. As a physician-scientist, Dr. Mendelsohn has studied signal transduction pathways regulating vascular and cardiac function and has published more than 150 papers. Dr. Mendelsohn received his B.A. from Amherst College in chemistry and English and his M.D. from Harvard Medical School.

LAWRENCE OLANOFF, M.D., Ph.D.
Medical University of South Carolina

Lawrence S. Olanoff, M.D., Ph.D. joined our board of directors in April 2015. Dr. Olanoff most recently served as chief operating officer for Forest Laboratories, Inc. (acquired by Allergan plc) from October 2006 to December 2010. Dr. Olanoff also served as a director of Forest from October 2006 to July 2014. From July 2005 to October 2006, Dr. Olanoff was president and chief executive officer at Celsion Corporation. He also served as executive vice president and chief scientific officer of Forest from 1995 to 2005. Prior to joining Forest in 1995, Dr. Olanoff served as senior vice president of clinical research and development at Sandoz Pharmaceutical Corporation (now a division of the Novartis Group) and at the Upjohn Company in a number of positions including corporate vice president of clinical development and medical affairs. In addition, he is currently an adjunct assistant professor and special advisor to the president for corporate relations at the Medical University of South Carolina (MUSC), an ex-officio director of the MUSC Foundation for Research Development, chairman of the board of the Clinical Biotechnology Research Institute at Roper St. Francis Hospital and a board member of Axovant Sciences Ltd., the Horizon Project and the Zucker Institute for Applied Neurosciences. Dr. Olanoff received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University.